This is a single arm, multi-institution (1) Hackensack Meridian Health at Hackensack, New Jersey (NJ) (2) Jersey Shore Medical Center, Neptune, NJ and (3) Georgetown/Lombardi Cancer Center) phase II study of the combination of pembrolizumab, belantamab, and dexamethasone in patients with triple class refractory multiple myeloma.
| SparkCures ID | 1307 |
|---|---|
| Trial Phase | Phase 1/2 |
| Enrollment | 64 Patients |
| Treatments |
|
| Trial Sponsors |
|
| Trial Collaborators |
|
| NCT Identifier |
|
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
Please visit the ClinicalTrials.gov page for historical site information.
View Centers